世界中の市場調査レポートを販売!当社に無いレポートもお探しします。

レポートナンバー 0000031331

ヒトマイクロバイオーム市場-世界の業界展望、総合的分析、予測、2021 - 2030

Fatpos Global

Human Microbiome Market - By Product (Probiotics, Prebiotics, Medical Foods, And Supplements), By Application (Therapeutics And Diagnostics) And By Disease Type (Obesity, Diabetes, Autoimmune Disorder, Metabolic & Gastrointestinal Disorders, And Cancer): Global Industry Perspective, Comprehensive Analysis And Forecast, 2021 - 2030

発刊日 2022/01

言語英語

体裁Word-PDF/173ページ

ライセンス/価格173ページ

0000031331

Single
Enterprise
Corporate

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※本レポートは、英文です。Word-PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

無料サンプル

  • サンプルはお問い合わせください。

レポート概要

ヒトマイクロバイオーム市場-製品別(プロバイオティクス、プレバイオティクス、病者用食品、サプリメント)、用途別(治療&診断)、疾患の種類別(肥満、糖尿病、自己免疫疾患、代謝、胃腸障害、癌):世界の業界展望、総合的分析と予測、2021年〜2030年

市場概要

Fatpos Globalは、Human Microbiome Market- Global Industry Perspective, Comprehensive Analysis And Forecast, 2021 - 2030というタイトルのレポートを発刊しました。Fatpos Globalの調査によると、2021年から2030年までの期間に、9.40%のCAGRで拡大し、2030年までに13億6,549万ドルに達すると予想されます。グローバル市場の総合的な見通しを示すために、市場規模、シェア、売上高、予測動向、供給、生産、需要、業界、CAGRなどのいくつかの決定的な要因を深く理解することに重点を置いています。

レポート詳細

目次

Contents

1. Executive Summary

2. Human Microbiome Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms

3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation

4. Average Pricing Analysis

5. Macro-Economic Indicators

6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends

7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix

8. Recent Development, Policies & Regulatory Landscape

9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis

10. Human Microbiome Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological

11. Human Microbiome Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

12. Human Microbiome Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By network type: Market Share (2020-2030F)
12.2.1. Hardware , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Software , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Services , By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By End user: Market Share (2020-2030F)
12.3.1. Manufacturing, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Healthcare, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Energy and Utilities, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. IT & Telecom, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Automotive and Transportation, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Supply Chain and Logistics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.7. Government and Public Safety, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.8. Agriculture, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.9. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F

Company Profile
Rebiotix, Osel, Inc., OBiome LLC,
Vedanta Biosciences,
Second Genome,
Seres Therapeutics,
Enterome Biosciences,
Metabiomics Corp.
, uBiome, Inc.,
and Synthetic Biologics, Inc.
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.

この商品のレポートナンバー

0000031331

TOP